Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats

Digestive Diseases and Sciences

Volumn 58, Issue 12, 2013, Pages 3534-3544

  Seo, Makoto ^a   Inoue, Ikuo ^a   Tanaka, Mamoru ^b   Matsuda, Noriko ^b   Nakano, Takanari ^a   Awata, Takuya ^a   Katayama, Shigehiro ^a   Alpers, David H ^c   Komoda, Tsugikazu ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Miyarisan Pharmaceutical Co   (Japan)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

CBM588; Diacylglycerol acyltransferase; Hepatic lipid droplets; Liver X receptor; Non alcoholic fatty liver disease; Peroxisome proliferator activated receptors

Indexed keywords

BILE ACID; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; DIACYLGLYCEROL ACYLTRANSFERASE 2; FAT DROPLET; FATTY ACID; LIVER PROTEIN; LIVER X RECEPTOR ALPHA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM BUTYRICUM MIYAIRI 588; CONTROLLED STUDY; FAT CONTENT; FECES LEVEL; FOOD INTAKE; GENE EXPRESSION; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID DIET; LIPID METABOLISM; LIPOLYSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; WESTERN BLOTTING;

ANIMALS; BODY WEIGHT; CLOSTRIDIUM BUTYRICUM; DIACYLGLYCEROL O-ACYLTRANSFERASE; EATING; FATTY LIVER; LIPID METABOLISM; LIVER; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84890125493     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2879-3     Document Type: Article

References (40)

1. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129-1133.
2. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
3. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899-905.
4. George J, Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol Pharm. 2008;5:49-59.
5. Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med. 2003;3:561-572.
6. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634-642.
7. Kang H, Greenson JK, Omo JT, et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol. 2006;101:2247-2253.
8. Solga S, Alkhuraishe AR, Clark JM, et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci. 2004;49:1578-1583.
9. Benno Y, Sawada K, Mitsuoka T. The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants. Microbiol Immunol. 1984;28:975-986.
10. Sato R, Tanaka M. Intestinal distribution and intraluminal localization of orally administered Clostridium butyricum in rats. Microbiol Immunol. 1997;41:665-671.
11. Ichikawa H, Kuroiwa T, Inagaki A, et al. Probiotic bacteria stimulate gut epithelial cell proliferation in rats. Dig Dis Sci. 1999;44:2119-2123.
12. Okamoto T, Sasaki M, Tsujikawa T, et al. Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J Gastroenterol. 2000;35:341-346.
13. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NFκB activation and cellular proteasome activity. J Biol Chem. 2001;276:44641-44646.
14. Seki H, Shiohara M, Matsumura T, et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int. 2003;45:86-90.
15. Takahashi M, Taguchi H, Yamaguchi H, et al. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice. FEMS Immunol Med Microbiol. 2004;41:219-226.
16. Ley RE, Turnbaugh PJ, Klein S, et al. Human gut microbes associated with obesity. Nature. 2006;444:1022-1023.
17. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027-1031.
18. DiBaise JK, Zhang H, Crowell MD, et al. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc. 2008;83:460-469.
19. Graber CD, O'Neal RM, Rabin ER. Effect of high fat diets on intestinal microflora and serum cholesterol in rats. J Bacteriol. 1965;89:47-51.
20. Midtvedt T. Microbial bile acid transformation. Am J Clin Nutr. 1974;27:1341-1347.
21. Hosomi M, Tanida N, Shimoyama T. The role of intestinal bacteria in gallstone formation in animal model. A study on biliary lipid composition and bile acid profiles in bile, small intestinal contents and feces of Clostridium butyricum MIYAIRI No. 588 monocontaminated mice. Gastroenterol Jpn. 1982;17:316-323.
22. Kobashi K, Takeda Y, Itoh H, et al. Cholesterol-lowering effect of Clostridium butyricum in cholesterol-fed rats. Digestion. 1983;26:173-178.
23. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497-509.
24. 4, 6-bile acids and related compounds in biological fluids of infants with cholestasis by gas chromatography-mass spectrometry. J Chromatogr B. 1997;693:11-21.
25. 4-3-oxo- steroid 5β-reductase deficiency by LC-ESI-MS/MS measurement of urinary bile acids. J Chromatogr B. 2012;900:24-31.
26. Bach Knudsen KE, Serena A, Canibe N, et al. New insight into butyrate metabolism. Proc Nutr Soc. 2003;62:81-86.
27. Stone SJ, Myers HM, Watkins SM, et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem. 2003;279:11767-11776.
28. Yamazaki T, Sasaki E, Kakinuma C, et al. Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1. J Biol Chem. 2005;280:21506-21514.
29. Ressell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137-174.
30. Bravo E, Flora L, Cantafora A, et al. The influence of dietary saturated and unsaturated fat on hepatic cholesterol metabolism and the biliary excretion of chylomicron cholesterol in the rat. Biochim Biophys Acta. 1998;16:134-148.
31. Shefer S, Nguyen LB, Salen G, et al. Differing effect of cholesterol and taurocholate on steady state hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities and mRNA levels in the rat. J Lipid Res. 1992;33:1193-1200.
32. Dikkers A, Tietge UJ. Biliary cholesterol secretion: more than a simple ABC. World J Gastroenterol. 2010;16:5936-5945.
33. Figge A, Lammert F, Paigen B, et al. Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis. J Biol Chem. 2004;279:2790-2799.
34. Sun F, Xie ML, Xue J, et al. Osthol regulates hepatic PPARα-mediated lipogenic gene expression in alcoholic fatty liver murine. Phytomedicine. 2010;17:669-673.
35. Gavrilova O, Haluzik M, Matsusue K, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003;278:34268-34276.
36. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res. 2005;51:85-94.
37. Chinetti G, Lestavel S, Bocher V, et al. R-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58.
38. Ogata M, Tsujita M, Hossain MA, et al. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 2009;205:413-419.
39. Kalaany NY, Mangelsdorf DJ. LXRs and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol. 2006;68:159-191.
40. Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology. 2011;140:1120-1125.